Status:
COMPLETED
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Lead Sponsor:
Marcelo F. Di Carli, MD, FACC
Collaborating Sponsors:
Society of Nuclear Medicine and Molecular Imaging
General Electric
Conditions:
High Grade Glioma
Eligibility:
All Genders
18-85 years
Brief Summary
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic mar...
Eligibility Criteria
Inclusion
- Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
- Anticipated survival ≥6 months
- Able to give informed consent
- Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
- Male or Female
Exclusion
- Prior radiation therapy and chemotherapy to the brain
- Active intracranial infection or nonglial brain mass.
- Recent large intracranial hemorrhage (\<1 month)
- Expected survival \<6 months
- Pregnant or nursing
- Renal failure
- Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01240161
Start Date
December 1 2009
End Date
March 1 2016
Last Update
August 29 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at San Diego
San Diego, California, United States, 92093
2
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115